ONCAlert | 2018 ASCO Annual Meeting

A Bispecific Immunotherapy for the Treatment of Melanoma

Mark R. Middleton, MD, PhD
Published Online: 8:31 PM, Thu April 23, 2015
Mark R. Middleton, MD, PhD, a professor of experimental cancer medicine at the University of Oxford, discusses the results of a phase I/IIa trial of IMCgp100, a bispecific immunotherapy, for the treatment of patients with melanoma.

<<< View more from the 2015 AACR Annual Meeting



Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.